Inflammatory Breast Cancer (IBC) | Susan G. Komen®
Inflammatory breast cancer (IBC) is an aggressive form of locally advanced breast cancer. Learn about IBC, the warning signs, diagnosis, treatment and more.| Susan G. Komen®
Inflammatory breast cancer (IBC) is an aggressive form of locally advanced breast cancer. Learn about IBC, the warning signs, diagnosis, treatment and more.| Susan G. Komen®
HER2-Targeted Therapies for Metastatic Breast Cancer Watch our June 2024 MBC Impact Series, Metastatic HER2-Positive Breast Cancer. HER2 and metastatic breast cancer The HER2 protein is an important driver of cell growth and survival. A pathologist determines HER2 status by testing a sample of the metastatic tumor (from a biopsy of the metastases). Learn more […]| Susan G. Komen®
Learn how rates of breast cancer in the U.S. vary by race and ethnicity. White women and Black women have the highest rates of breast cancer overall.| Susan G. Komen®
Is there a connection between exercise and breast cancer risk? Review the effects of physical activity on breast cancer patients.| Susan G. Komen®
Your pathology report contains the information that describes your breast cancer diagnosis.| Susan G. Komen®
Invasive Lobular Breast Cancer Watch our Mission Moment webinar, Invasive Lobular Breast Cancer. Read our fact sheet on invasive lobular breast cancer. What is invasive lobular breast cancer? Invasive lobular cancer or infiltrating lobular carcinoma (ILC) is invasive breast cancer that begins in the lobules of the breast. The lobules are small, round sacs in […]| Susan G. Komen®
Learn about male breast cancer. Review statistics, warning signs, risk factors and types of breast cancer in men.| Susan G. Komen®
CDK4/6 Inhibitors for Metastatic Breast Cancer CDK4 and CDK6 are enzymes important in cell division. CDK4/6 inhibitors are drugs designed to interrupt the growth of cancer cells. CDK4/6 inhibitors are used in combination with hormone therapy to treat some hormone receptor-positive breast cancers. The CDK4/6 inhibitors FDA-approved for metastatic breast cancer treatment are: Drug name […]| Susan G. Komen®
Hormone Therapy for Metastatic Breast Cancer Watch Susan G. Komen®’s January 2024 MBC Impact Series, Metastatic Breast Cancer and Estrogen Receptor-Positive Breast Cancer. What is hormone therapy? Estrogen and progesterone are female hormones produced in the body. Some breast cancer cells need estrogen and/or progesterone to grow. When these hormones attach to special proteins called […]| Susan G. Komen®
Learn about types of invasive breast tumors and how different tumor types affect prognosis.| Susan G. Komen®
Learn how breast cancer is staged and the stages of breast cancer.| Susan G. Komen®
Hormone receptor status and HER2 status are the main factors in planning breast cancer treatment.| Susan G. Komen®
Learn about surgery for breast cancer. Surgery may be lumpectomy (breast-conserving surgery) or mastectomy, and may include breast reconstruction (reconstructive surgery).| Susan G. Komen®
In this episode of Breast Cancer Breakthroughs, we speak with Komen grantees Dr. Tarah Ballinger, medical oncologist at Indiana University School of Medicine, and Dr. Pedram Razavi, medical oncologist at Memorial Sloan Kettering Cancer Center, about the biggest highlights from the 2024 ASCO Annual Meeting and what they could mean for patients.| Susan G. Komen®
